0 CHECKOUT

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015

  • ID: 3275730
  • May 2015
  • 67 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Agilvax, Inc.
  • Anaconda Pharma
  • Biogenomics Limited
  • BioMAS Ltd.
  • Helix BioPharma Corp.
  • LEO Pharma A/S
  • MORE

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015

Summary

The‘Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015’, provides an overview of the Genital Warts (Condylomata Acuminata)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agilvax, Inc.
  • Anaconda Pharma
  • Biogenomics Limited
  • BioMAS Ltd.
  • Helix BioPharma Corp.
  • LEO Pharma A/S
  • MORE

List of Tables

List of Figures

Introduction

Report Coverage

Genital Warts (Condylomata Acuminata) Overview

Therapeutics Development

Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview

Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis

Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies

Genital Warts (Condylomata Acuminata) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Genital Warts (Condylomata Acuminata) - Products under Development by Companies

Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development

Agilvax, Inc.

Anaconda Pharma

Biogenomics Limited

BioMAS Ltd.

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Helix BioPharma Corp.

LEO Pharma A/S

MediGene AG

NanoViricides, Inc.

Novan, Inc.

Tamir Biotechnology, Inc.

Genital Warts (Condylomata Acuminata) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AP-611074 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AX-03 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HerpeCide-I - Drug Profile

Product Description

Mechanism of Action

R&D Progress

human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imiquimod - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ingenol mebutate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

interferon alfa-2b (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

interferon alpha-2b (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PP-210 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SB-206 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sinecatechins - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates

Genital Warts (Condylomata Acuminata) - Dormant Projects

Genital Warts (Condylomata Acuminata) - Discontinued Products

Genital Warts (Condylomata Acuminata) - Product Development Milestones

Featured News & Press Releases

Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries

Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries

Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen

Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland

Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen® in United Kingdom and Ireland

Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden

Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia

Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan

Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada

Jul 29, 2013: Medigene: Market launch of Veregen in the Netherlands started

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015

Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Late Stage Development, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Anaconda Pharma, H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by MediGene AG, H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2015

Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2015

Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2015

Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2015

List of Figures:

Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2015

Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Products, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Agilvax, Inc.
- Anaconda Pharma
- Biogenomics Limited
- BioMAS Ltd.
- Foamix Pharmaceuticals Ltd.
- G&E Herbal Biotechnology Co., Ltd.
- Helix BioPharma Corp.
- LEO Pharma A/S
- MediGene AG
- NanoViricides, Inc.
- Novan, Inc.
- Tamir Biotechnology, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.